What is APD403 oral used for?

APD403 oral is indicated for Prevention of postoperative shivering.

Who makes APD403 oral?

APD403 oral is developed by Acacia Pharma Ltd.

What are the side effects of APD403 oral?

Common side effects include Nausea, Vomiting, Headache.

Last reviewed 2026-04-23 · How we verify

APD403 oral

Acacia Pharma Ltd · Phase 2 active Small molecule

APD403 is a selective α2δ-1 subunit ligand.

APD403 is a selective α2δ-1 subunit ligand. Used for Prevention of postoperative shivering.

At a glance

Generic name	APD403 oral
Sponsor	Acacia Pharma Ltd
Drug class	α2δ-1 subunit ligand
Target	α2δ-1 subunit
Modality	Small molecule
Therapeutic area	Anesthesiology
Phase	Phase 2

Mechanism of action

APD403 is a selective α2δ-1 subunit ligand that modulates the activity of voltage-gated calcium channels. This mechanism is thought to contribute to its analgesic effects. APD403 has been investigated for its potential to reduce the risk of postoperative shivering.

Approved indications

Prevention of postoperative shivering

Common side effects

Nausea
Vomiting
Headache

Key clinical trials

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results